PBM reform, including spread pricing, AWP setting and/or dispense rate policy, ASP policy, any willing pharmacy laws in Medicare, third party essential medicine testing
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.
PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty, most favored nations executive order, AWP reform, U.S. manufacturer preferencing, Medicare conditions of participation relating to resiliency standards linked to government reimbursement, 340b reform including PBM-owned 340b pharmacies, Medicare formulary policy and specialty tier reform, generics on generic tiers, Medicaid generics penalty, IRA inflationary penalty, manufacturer discount program
BEAT, AMT, U.S. manufacturing incentives
Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP
Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers
Section 232 investigation into pharmaceuticals and unfair trade practices